Technology Accumulation Since 2019

Enhancing Health Equity in Laos

Affordable pharmaceutical solutions through TRIPS-compliant production and international collaboration

About Laobeacon

Our Vision

Enhancing Health Equity in Laos through accessible, affordable pharmaceutical solutions that meet international quality standards.

Our Mission

We are committed to producing high-quality, TRIPS-compliant pharmaceutical products through strategic international collaboration with partners in China, Bangladesh, India, Hong Kong, and Japan.

Core Values

Affordability

Making essential medicines accessible to all communities

TRIPS Compliance

Adhering to international intellectual property standards

International Collaboration

Partnering with global experts for knowledge transfer

Our Products

Oral Solid Dosage (OSD) Pharmaceutical Solutions

⚠️ Product availability and regulatory compliance vary by region. Please consult local regulations and healthcare professionals.

Ponatinib15mg / 45mg

Ponatinon

A third-generation BCR-ABL tyrosine kinase inhibitor for chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).

Eltrombopag25mg / 50mg

Eltrombon

A thrombopoietin receptor agonist used to treat thrombocytopenia in patients with chronic immune thrombocytopenia (ITP), chronic hepatitis C, and severe aplastic anemia.

Osimertinib80mg

Osimerton

A third-generation EGFR tyrosine kinase inhibitor for the treatment of metastatic EGFR T790M mutation-positive non-small cell lung cancer (NSCLC).

Avatrombopag20mg

Avatrombon

A thrombopoietin receptor agonist for the treatment of thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo a procedure.

Trelagliptin50mg / 100mg

Trelaglipon

A long-acting DPP-4 inhibitor for the treatment of type 2 diabetes mellitus, administered once weekly.

Capmatinib200mg

Capmatinon

A MET inhibitor for the treatment of metastatic non-small cell lung cancer (NSCLC) with MET exon 14 skipping alterations.

Sotorasib120mg

Sotorasibon

A KRAS G12C inhibitor for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC).

Gilteritinib40mg

Gilteriton

A FLT3 inhibitor for the treatment of relapsed or refractory acute myeloid leukemia (AML) with a FLT3 mutation.

Selpercatinib40mg / 80mg

Selpercatinon

A RET inhibitor for the treatment of RET fusion-positive non-small cell lung cancer (NSCLC), RET-mutant medullary thyroid cancer (MTC), and RET fusion-positive thyroid cancer.

The Future of Global Health

Join us in our mission to enhance health equity across Southeast Asia and beyond.

Sales Experts

We seek experienced pharmaceutical sales professionals with global vision and regional expertise.

Global vision, regional market knowledge, and passion for healthcare accessibility required.

Equity Incentive System

We offer equity incentives to core contributors who share our vision and commitment to long-term growth.

Medical Impact Investment

Invest in the future of accessible healthcare while generating sustainable returns.

Market Opportunity

Southeast Asia's growing pharmaceutical market presents significant growth potential.

Sustainable Growth

TRIPS-compliant production model ensures long-term viability and scalability.

Social Impact

Generate returns while improving healthcare access for underserved populations.

Healing the World

Our commitment to social responsibility extends beyond manufacturing to community health support.

Pharmacy Donations

We regularly donate essential medicines to underserved communities and healthcare facilities.

Community Health Programs

Supporting local health initiatives and education programs to promote preventive care.

Humanitarian Aid

Providing emergency pharmaceutical support during natural disasters and health crises.